ClinicalTrials.gg
Active, not recruitingNCT03937219COSMIC-313Updated Oct 20, 2026Results posted

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

A Phase 3 interventional study of Cabozantinib and Nivolumab in Renal Cell Carcinoma, sponsored by Exelixis. Active, not recruiting at 159 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
855
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.

Enrollment
5th of 42
855 · median 44
Started
2019
with 5 others
Phase 3
6 of 42
2 open now
Primary completion
2022-01
later than 1 of 22 live
Registered
19th of 42
by date
Lead sponsor
5 of 42
Exelixis

Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 5th largest by enrollment, is one of 6 that started in 2019, is one of 6 in phase 3, reaches primary completion later than 1 of the 22 other live ones, and was the 19th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 42 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing cabozantinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.

Read the detailed description

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. The primary objective of this study is to evaluate the effect of cabozantinib in combination with nivolumab and ipilimumab ("triplet") on the duration of progression-free survival (PFS) versus nivolumab and ipilimumab. A secondary objective is to evaluate the effect of triplet combination on the duration of overall survival (OS).

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • renal
  • cancer
  • carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed advanced (not amenable to curative surgery or radiation therapy) or (AJCC Stage IV) renal cell carcinoma with a clear-cell component.
  • Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database Consortium (IMDC) criteria.
  • per 1.1 as determined by the Investigator. Measurable disease must be outside the radiation field if radiation therapy was previously administered.
  • Performance Status (KPS) ≥ 70%.
  • Adequate organ and marrow function.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anticancer therapy for unresectable locally advanced or RCC including agents.
  • Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks prior to randomization.
  • Known or cranial epidural disease unless adequately treated with radiotherapy and stable for at least 4 weeks prior to randomization.
  • Concomitant anticoagulation with oral anticoagulants or inhibitors.
  • Administration of a live, attenuated vaccine within 30 days prior to randomization.
  • Uncontrolled, significant intercurrent or recent illness including, but not limited to serious cardiovascular disorders (including uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment), GI disorders associated with high risk for perforation or fistula formation, tumors invading GI tract, bowel obstruction, intra-abdominal abscess, bleeding events, cavitating pulmonary lesions, or lesions invading major pulmonary blood vessels.
  • Other clinically significant disorders such as:

    • disease that has been symptomatic or required treatment within the past two years from the date of randomization.
    • Any condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) or other medications within 14 days of randomization.
    • Active infection requiring systemic treatment. Acute or chronic or C infection, known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known positive test for tuberculosis infection where there is clinical or radiographic evidence of active myobacterial infection.
    • Known history of COVID-19 unless the subject has clinically recovered from the disease at least 30 days prior to randomization.
  • Major surgery (eg, nephrectomy, GI surgery, removal or of brain metastasis) within 4 weeks prior to randomization. Minor surgeries within 10 days prior to randomization. Subjects must have complete wound healing from major or minor surgery before randomization.
  • Any other active at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
855 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab

    Drug: Cabozantinib · Biological: Nivolumab · Biological: Ipilimumab

  • Active comparator
    Control Arm

    Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab

    Biological: Nivolumab · Biological: Ipilimumab · Drug: Cabozantinib-matched placebo

Interventions

  • Specified dose on specified days.

    Also known as: Cabometyx, XL184

  • BiologicalNivolumab

    Specified dose on specified days.

    Also known as: Opdivo, BMS-936558

  • BiologicalIpilimumab

    Specified dose on specified days.

    Also known as: Yervoy, BMS-734016

  • DrugCabozantinib-matched placebo

    Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)

    Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause. PFS (months) = (earliest date of progression, death, censoring - date of randomization + 1)/30.4375. PFS was determined as per Response Evaluation Criteria in Solid Tumors version (RECIST) v1.1.

    Time frame: Up to 32 months

Secondary outcomes

  1. Duration of Overall Survival (OS)

    Duration of OS (months) = (earliest date of death or censoring - date of randomization + 1)/30.4375.

    Time frame: Up to 58 months

07

Results

Posted Sep 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneCabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + Ipilimumab
Started428427
Received at least 1 dose of study drug426423
Progression free survival (pfs) intent-to-treat (pitt) population276274
Safety analysis set426423
Intent to treat (itt) population428427
Completed185187
Not completed243240
Withdrew: Death223211
Withdrew: Withdrawal by subject1725
Withdrew: Lost to follow-up34

Outcome measures

PrimaryDuration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)

Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause. PFS (months) = (earliest date of progression, death, censoring - date of randomization + 1)/30.4375. PFS was determined as per Response Evaluation Criteria in Solid Tumors version (RECIST) v1.1.

Time frame:
Up to 32 months
Reported as:
Median · months
Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)
monthsCabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + Ipilimumab
Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)NA (14.00 to NA)11.30 (7.69 to 18.17)
Statistical analysis
  • Cabozantinib + Nivolumab + Ipilimumab vs Placebo + Nivolumab + Ipilimumab · Log Rank · p = 0.0131 · Hazard ratio (hr): 0.73 · 95% CI 0.57 to 0.94
SecondaryDuration of Overall Survival (OS)

Duration of OS (months) = (earliest date of death or censoring - date of randomization + 1)/30.4375.

Time frame:
Up to 58 months
Reported as:
Median · months
Duration of Overall Survival (OS)
monthsCabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + Ipilimumab
Duration of Overall Survival (OS)41.86 (34.79 to 47.87)41.99 (34.92 to 53.13)

Adverse events

Collected over Day 1 up to 58 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib + Nivolumab + Ipilimumab224/426 (52.6%)272/426 (63.8%)421/426 (98.8%)
Placebo + Nivolumab + Ipilimumab217/423 (51.3%)257/423 (60.8%)416/423 (98.3%)
Most frequent serious events
Showing 10 of 347
Most frequent serious events
EventCabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + Ipilimumab
Alanine aminotransferase increasedInvestigations45/42611/423
Aspartate aminotransferase increasedInvestigations34/42613/423
Immune-mediated hepatitisHepatobiliary disorders20/4263/423
DiarrhoeaGastrointestinal disorders14/42617/423
COVID-19Infections and infestations16/42617/423
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/42615/423
PneumoniaInfections and infestations13/42610/423
Adrenal insufficiencyEndocrine disorders11/42612/423
ColitisGastrointestinal disorders5/42610/423
VomitingGastrointestinal disorders2/4269/423
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + Ipilimumab
DiarrhoeaGastrointestinal disorders216/426108/423
Alanine aminotransferase increasedInvestigations204/42689/423
Aspartate aminotransferase increasedInvestigations195/42674/423
FatigueGeneral disorders133/426129/423
PruritusSkin and subcutaneous tissue disorders106/426131/423
HypertensionVascular disorders125/42645/423
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders123/42626/423
HypothyroidismEndocrine disorders122/42681/423
Decreased appetiteMetabolism and nutrition disorders118/42684/423
NauseaGastrointestinal disorders112/426105/423

Baseline characteristics

The Intent-to-Treat (ITT) population was defined as all randomized participants regardless of whether any study treatment or the correct study treatment was received.

Age, Categorical
Age, Categorical(Participants)Cabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + IpilimumabTotal
<=18 years000
Between 18 and 65 years277276553
>=65 years151151302
Sex: Female, Male
Sex: Female, Male(Participants)Cabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + IpilimumabTotal
Female102115217
Male326312638
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + IpilimumabTotal
Hispanic or Latino130127257
Not Hispanic or Latino263273536
Unknown or Not Reported352762
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cabozantinib + Nivolumab + IpilimumabPlacebo + Nivolumab + IpilimumabTotal
American Indian or Alaska Native41014
Asian293362
Native Hawaiian or Other Pacific Islander022
Black or African American369
White339331670
More than one race224
Unknown or Not Reported514394
08

Study locations

159 sites
  • Exelixis Clinical Site #116
    La Jolla, California 92093, United States
  • Exelixis Clinical Site #166
    Orange, California 92868-3201, United States
  • Exelixis Clinical Site #29
    Boca Raton, Florida 33486, United States
  • Exelixis Clinical Site #44
    Miami, Florida 33176, United States
  • Exelixis Clinical Site #3
    Atlanta, Georgia 30318, United States
  • Exelixis Clinical Site #95
    Chicago, Illinois 60612, United States
  • Exelixis Clinical Site #69
    Scarborough, Maine 04074, United States
  • Exelixis Clinical Site #58A
    Baltimore, Maryland 21287, United States
  • Exelixis Clinical Site #7B
    Boston, Massachusetts 02114, United States
  • Exelixis Clinical Site #7A
    Boston, Massachusetts 02215, United States
  • Exelixis Clinical Site #7C
    Boston, Massachusetts 02215, United States
  • Exelixis Clinical Site #6
    Burlington, Massachusetts 01805, United States
  • Exelixis Clinical Site #15
    Detroit, Michigan 48201, United States
  • Exelixis Clinical Site #24
    Kansas City, Missouri 64132, United States
  • Exelixis Clinical Site #4
    St Louis, Missouri 63110, United States
  • Exelixis Clinical Site #2
    Omaha, Nebraska 68130, United States
  • Exelixis Clinical Site #159
    New York, New York 10032, United States
  • Exelixis Clinical Site #8
    New York, New York 10065, United States
  • Exelixis Clinical Site #19
    Syracuse, New York 13210, United States
  • Exelixis Clinical Site #101
    Charlotte, North Carolina 28204, United States
  • Exelixis Clinical Site #107
    Portland, Oregon 97239, United States
  • Exelixis Clinical Site #12
    Pittsburgh, Pennsylvania 15232, United States
  • Exelixis Clinical Site #102
    Charleston, South Carolina 29425, United States
  • Exelixis Clinical Site #5
    Myrtle Beach, South Carolina 29572, United States
  • Exelixis Clinical Site #10
    Nashville, Tennessee 37203, United States
  • Exelixis Clinical Site #38
    Nashville, Tennessee 37232, United States
  • Exelixis Clinical Site #64
    Fairfax, Virginia 22031, United States
  • Exelixis Clinical Site #57
    Seattle, Washington 98109, United States
  • Exelixis Clinical Site #1
    Spokane, Washington 99208, United States
  • Exelixis Clinical Site #13
    Madison, Wisconsin 53792, United States
  • Exelixis Clinical Site #153
    Pilar, Buenos Aires B1629ODT, Argentina
  • Exelixis Clinical Site #109
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Exelixis Clinical Site #73
    San Miguel de Tucumán, Tucumán Province T4000, Argentina
  • Exelixis Clinical Site #54
    Buenos Aires, C1125ABD, Argentina
  • Exelixis Clinical Site #63
    CABA, C1120AAT, Argentina
  • Exelixis Clinical Site #110
    Ciudad Autonoma de Buenos Aire, C1426ANZ, Argentina
  • Exelixis Clinical Site #120
    Córdoba, X5004, Argentina
  • Exelixis Clinical Site #32
    Albury, New South Wales 2640, Australia
  • Exelixis Clinical Site #35
    Kogarah, New South Wales 2217, Australia
  • Exelixis Clinical Site #27
    North Ryde, New South Wales 2109, Australia
  • Exelixis Clinical Site #33
    Sydney, New South Wales 2065, Australia
  • Exelixis Clinical Site #17
    South Brisbane, Queensland 4101, Australia
  • Exelixis Clinical Site #14
    Woolloongabba, Queensland 4102, Australia
  • Exelixis Clinical Site #18
    Adelaide, South Australia 5000, Australia
  • Exelixis Clinical Site #11
    North Adelaide, South Australia 5006, Australia
  • Exelixis Clinical Site #9
    Ballarat, Victoria 3350, Australia
  • Exelixis Clinical Site #23
    Box Hill, Victoria 3128, Australia
  • Exelixis Clinical Site #26
    Subiaco, Western Australia 6008, Australia
  • Exelixis Clinical Site #98
    Wiener Neustadt, Lower Austria 2700, Austria
  • Exelixis Clinical Site #76
    Linz, Upper Austria 4020, Austria
  • Exelixis Clinical Site #75
    Salzburg, 5020, Austria
  • Exelixis Clinical Site #126
    Vienna, 1090, Austria
  • Exelixis Clinical Site #112
    Brussels, 1000, Belgium
  • Exelixis Clinical Site #146
    Hasselt, 3500, Belgium
  • Exelixis Clinical Site #154
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Exelixis Clinical Site #155
    Curitiba, Paraná 80530-010, Brazil
  • Exelixis Clinical Site #158
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Exelixis Clinical Site #140
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Exelixis Clinical Site #163
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Exelixis Clinical Site #168
    Barretos, São Paulo 14784-400, Brazil
  • Exelixis Clinical Site #162
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Exelixis Clinical Site #119
    São Paulo, 01323-001, Brazil
  • Exelixis Clinical Site #141
    São Paulo, 01327-001, Brazil
  • Exelixis Clinical Site #22
    Calgary, Alberta T2N 4N2, Canada
  • Exelixis Clinical Site #105
    Winnipeg, Manitoba R3E 0V9, Canada
  • Exelixis Clinical Site #46
    Ottawa, Ontario K1H 8L6, Canada
  • Exelixis Clinical Site #25
    Toronto, Ontario M4N 3M5, Canada
  • Exelixis Clinical Site #113
    Montreal, Quebec H3T 1E2, Canada
  • Exelixis Clinical Site #85
    Temuco, Región de La Araucanía (IX) 4810561, Chile
  • Exelixis Clinical Site #91
    Santiago, 7500921, Chile
  • Exelixis Clinical Site #100
    Santiago, 8420383, Chile
  • Exelixis Clinical Site #89
    Králová, 50005, Czechia
  • Exelixis Clinical Site #114
    Prague, 140 59, Czechia
  • Exelixis Clinical Site #118
    Prague, 150 06, Czechia
  • Exelixis Clinical Site #50
    Helsinki, 00029, Finland
  • Exelixis Clinical Site #56
    Tampere, 33520, Finland
  • Exelixis Clinical Site #52
    Turku, 20520, Finland
  • Exelixis Clinical Site #86
    Bordeaux, 33075, France
  • Exelixis Clinical Site #71
    Le Mans, 72000, France
  • Exelixis Clinical Site #78
    Lyon, 69373, France
  • Exelixis Clinical Site #80
    Montpellier, 34295, France
  • Exelixis Clinical Site #66
    Nice, 06189, France
  • Exelixis Clinical Site #150
    Paris, 75015, France
  • Exelixis Clinical Site #65
    Reims, 51726, France
  • Exelixis Clinical Site #125
    Rennes, 35042, France
  • Exelixis Clinical Site #128
    Strasbourg, 67000, France
  • Exelixis Clinical Site #90
    Strasbourg, 67200, France
  • Exelixis Clinical Site #42
    Toulouse, 31059, France
  • Exelixis Clinical Site #67
    Vandœuvre-lès-Nancy, 54519, France
  • Exelixis Clinical Site #37
    Villejuif, 94800, France
  • Exelixis Clinical Site #127
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Exelixis Clinical Site #115
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Exelixis Clinical Site #117
    Frankfurt am Main, Hesse 60596, Germany
  • Exelixis Clinical Site #139
    Münster, North Rhine-Westphalia 48149, Germany
  • Exelixis Clinical Site #171
    Münster, North Rhine-Westphalia 90419, Germany
  • Exelixis Clinical Site #164
    Mainz, Rhineland-Palatinate 55131, Germany
  • Exelixis Clinical Site #137
    Jena, Thuringia 077477, Germany
  • Exelixis Clinical Site #124
    Dresden, 01307, Germany
  • Exelixis Clinical Site #28
    Hong Kong, Hong Kong
  • Exelixis Clinical Site #136
    Shatin, Hong Kong

Showing the first 100 of 159 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. PubMed 37163623 ↗
  • Labriola MK, George DJ. Setting a new standard for long-term survival in metastatic kidney cancer. Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5. No abstract available. PubMed 35383907 ↗
  • Mar N, Kaakour D, Rezazadeh Kalebasty A. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges. JCO Oncol Pract. 2022 Mar;18(3):197-199. doi: 10.1200/OP.21.00446. Epub 2021 Sep 22. No abstract available. PubMed 34550754 ↗
  • Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2. PubMed 33058158 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jan 2022, 31 months.

Results were first posted in Sep 2025, 3 years 7 months after primary completion. A results delay was requested in Jan 2023.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 31 months is below that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2019
First posted
May 3, 2019
StartActual
Jun 25, 2019
Primary completionActual
Jan 31, 2022
CompletionEst.
Jan 31, 2027
Results delay requested
Jan 23, 2023
Results first posted
Sep 10, 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03937219
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
May 3, 2019
Start date
Jun 25, 2019
Primary completion
Jan 31, 2022
Completion
Jan 31, 2027 (estimated)
Results posted
Sep 10, 2025
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion